Revolution Medicines reports that daraxonrasib doubled the overall survival of patients with metastatic pancreatic cancer from 6.6 to 13.2 months compared to standard chemotherapy. The post Pancreatic Cancer Drug Doubles Survival While Reducing Side Effects appeared first on Inside Precision Medicine .